



## The Application of DNA Methylation in Cancers

Guest Editors:

### Dr. Tomasz K. Wojdacz

1. Independent Clinical Epigenetics Laboratory, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Zachodniopomorskie, Poland
2. Aarhus Institute of Advanced Studies, Aarhus University, 8000 Aarhus C, Denmark

### Dr. Matthew Rose-Zerilli

1. Cancer Sciences Unit, University of Southampton, Southampton, UK
2. Institute for Life Sciences, University of Southampton, Southampton, UK

Deadline for manuscript submissions:

**closed (15 October 2022)**

### Message from the Guest Editors

DNA methylation is one of the most common covalent modifications of nucleotides in the DNA strand in humans. This modification has been known since the beginning of the last century and its significance in the development of not only cancer but also almost all types of diseases has been demonstrated in a vast number of publications. However, it is only recently that DNA methylation has begun to impact medical practice. With the personalized approach to patient treatment becoming a reality in clinical work, disease-related methylation changes are a rich source of biomarkers, helpful in the assessment of individual predisposition to disease and suitable for the early detection of disease, as well as being used as prognostic and predictive biomarkers for clinical disease management. Moreover, as DNA methylation is an enzymatic process and thus, potentially reversible, an increasing number of compounds targeting disease-related methylation changes are being tested in clinical trials. With the above in mind, the aim of this Special Issue is to feature papers that show translation applications of DNA methylation in both in vitro diagnostics and the treatment of cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)